Thursday, July 2, 2015

Tuesday Features

Regenicin readying clinical trials of NovaDerm skin substitute

Regenicin readying clinical trials of NovaDerm skin substitute

Regenicin (OTC:RGIN) is completing validation of its NovaDerm skin substitute at a leading institute of technology in the U.S and plans to seek FDA approval to move into clinical trials in the second half of 2015 as well as file for worldwide designation of NovaDerm as an orphan product. Randall McCoy “We expect to be in the clinic before the end... [Read more of this feature]


biOasis to file IND for HER2+ brain cancer treatment in 2016

biOasis to file IND for HER2+ brain cancer treatment in 2016

biOasis (OTCQX:BIOAF; TSX-V:BTI) hopes to file an Investigational New Drug application with the FDA next year to begin human testing of its Transcend platform against HER2 positive brain tumors, which result from HER2+ breast cancer metastasizing to the brain. Rob Hutchison “Given the significant unmet medical need of this condition, we are in discussions... [Read more of this feature]


Inogen POCs represent paradigm shift in oxygen therapy

Inogen POCs represent paradigm shift in oxygen therapy

Inogen (NASDAQ:INGN) is continuing to convert patients with lung disease from bulky oxygen tanks that need to be refilled every two weeks to its lightweight, portable oxygen concentrator (POC) that continuously extracts oxygen from the air in the atmosphere and can be carried over the shoulder. Alison Bauerlein “With POCs, patients can breathe easy... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Underwriters exercise Dipexium over-allotment option

Underwriters exercise Dipexium over-allotment option

Dipexium Pharmaceuticals (NASDAQ:DPRX) has closed a public offering of 1,480,000 common shares and underwriters also exercised their over-allotment option in full to purchase an additional 222,000 shares of common stock. Net proceeds of approximately $19.7-million will be used to fund operations and for other general corporate purposes, including, but... [Read more of this brief]


HCW starts Novogen at buy

HCW starts Novogen at buy

H.C. Wainwright has launched coverage of Novogen (NASDAQ:NVGN) with a “buy” rating and $8.50 price target. The stock closed at $4.02 on Tuesday. Novogen of Australia is developing novel therapies against cancer stem cells. The company has developed two drug families, super-benzopyrans (SBPs) and anti-tropomyosins (ATMs), for the treatment of solid... [Read more of this brief]


ViewRay secures up to $50-million from CRG

ViewRay secures up to $50-million from CRG

Closely-held ViewRay, makers of MRIdian, the world’s first and only clinical MRI-guided radiation therapy system, has secured up to $50-million in debt financing from CRG (formerly Capital Royalty L.P.), a healthcare investment firm. Through the transaction with CRG, ViewRay will initially access $30-million of debt, which is interest only for three... [Read more of this brief]


BioLight obtains CE Mark for CellDetect test

BioLight obtains CE Mark for CellDetect test

BioLight Life Sciences Investments’ (OTC:BLGTY; TASE:BOLT) CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories. In addition, the European Patent Office has issued a patent related to the core of the CellDetect technology. The patent... [Read more of this brief]


Analysts start EndoChoice at outperform, buy

Analysts start EndoChoice at outperform, buy

William Blair and Stifel initiated coverage of EndoChoice Holdings (NYSE:GI) with “outperform” and “buy” ratings, respectively. EndoChoice’s comprehensive portfolio of single-use GI endoscopy products and pathology/endoscopy services offers GI specialists (gastroenterologists) a unique, “one-stop shop” for all endoscopy procedure... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+